Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1-84. (Cancelled)

85. (Previously Presented) A method of treating an autoimmune system disease or disorder comprising administering to an individual, an effective amount of an antagonistic antibody or portion thereof that specifically binds a protein consisting of an amino acid sequence of amino acid residues 134-285 of SEQ ID NO:2.

86. (Previously Presented) The method of claim 85 wherein the antibody or portion thereof is a monoclonal antibody.

87. (Previously Presented) The method of claim 85 wherein the antibody or portion thereof is a polyclonal antibody.

88. (Previously Presented) The method of claim 85 wherein the antibody or portion thereof is a Fab fragment.

89. (Previously Presented) The method of claim 85 wherein the antibody or portion thereof is labeled.

90. (Previously Presented) The method of claim 89 wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

91. (Previously Presented) The method of claim 90 wherein the label is a radioisotope selected from the group consisting of:

(a) ^{125}I;

(b) ^{121}I;

(c) ^{131}I;

(d) ^{112}In; and

(e) ^{99m}Tc.

92-117. (Cancelled)

118. (Previously Presented) A method of treating rheumatoid arthritis comprising administering to an individual, an effective amount of an antagonistic antibody or portion thereof that specifically binds a protein consisting of the amino acid sequence of amino acid residues 134-285 of SEQ ID NO:2.

119. (Previously Presented) The method of claim 118 wherein the antibody or portion thereof is a monoclonal antibody.

120. (Previously Presented) The method of claim 118 wherein the antibody or portion thereof is a polyclonal antibody.

121. (Previously Presented) The method of claim 118 wherein the antibody or portion thereof is a Fab fragment.

122. (Previously Presented) The method of claim 118 wherein the antibody or portion thereof is labeled.

123. (Previously Presented) The method of claim 122 wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

124. (Previously Presented) The method of claim 123 wherein the label is a radioisotope selected from the group consisting of:

(a) ^{125}I;

(b) ^{121}I;

(c) ^{131}I;

(d) ^{112}In; and

(e) ^{99m}Tc.

125-147. (Cancelled)

148. (Previously Presented) A method of inhibiting B lymphocyte proliferation, differentiation or survival comprising administering to an individual or a cell culture containing B lymphocytes, an effective amount of an antagonistic antibody or portion thereof that specifically binds a protein consisting of an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of amino acid residues n to 285 of SEQ ID NO:2, where n is an integer in the range of 2-190;

(b) the amino acid sequence of amino acid residues 1 to m of SEQ ID NO:2, where m is an integer in the range of 274 to 284; and

(c) the amino acid sequence of amino acid residues n to m of SEQ ID NO:2, where n is an integer in the range of 2-190 and m is an integer in the range of 274-284.

149. (Previously Presented) The method of claim 148 wherein the protein consists of amino acid sequence (a).

150. (Previously Presented) The method of claim 148 wherein the protein consists of amino acid sequence (b).

151. (Previously Presented) The method of claim 148 wherein the protein consists of amino acid sequence (c).

152. (Previously Presented) The method of claim 148 wherein the antibody or portion thereof is a monoclonal antibody.

153. (Previously Presented) The method of claim 148 wherein the antibody or portion thereof is a polyclonal antibody.

154. (Previously Presented) The method of claim 148 wherein the antibody or portion thereof is a Fab fragment.

155. (Previously Presented) The method of claim 148 wherein the antibody or portion thereof is labeled.

156. (Previously Presented) The method of claim 155 wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

157. (Previously Presented) The method of claim 156 wherein the label is a radioisotope selected from the group consisting of:

(a) ^{125}I;

(b) ^{121}I;

(c) ^{131}I;

(d) ^{112}In; and

(e) ^{99m}Tc.

158. (Previously Presented) A method of inhibiting B lymphocyte proliferation, differentiation, or survival comprising administering to an individual or a cell culture containing B lymphocytes, an effective amount of an antagonistic antibody or portion thereof that specifically binds a protein consisting of an amino acid sequence of amino acid residues 134-285 of SEQ ID NO:2.

159. (Previously Presented) The method of claim 158 wherein the antibody or portion thereof is a monoclonal antibody.

160. (Previously Presented) The method of claim 158 wherein the antibody or portion thereof is a polyclonal antibody.

161. (Previously Presented) The method of claim 158 wherein the antibody or portion thereof is a Fab fragment.

162. (Previously Presented) The method of claim 158 wherein the antibody or portion thereof is labeled.

163. (Previously Presented) The method of claim 162 wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

164. (Previously Presented) The method of claim 163 wherein the label is a radioisotope selected from the group consisting of:

(a) ^{125}I;

(b) ^{121}I;

(c) ^{131}I;

(d) ^{112}In; and

(e) ^{99m}Tc.

165. (Previously Presented) The method of claim 85 wherein the autoimmune disease or disorder is systemic lupus erythematosus.

166. (Previously Presented) A method of treating an autoimmune disease or disorder comprising administering to an individual, an effective amount of an antagonistic antibody or portion thereof that specifically binds to an isolated recombinant Neutrokine-α protein purified from a cell culture wherein the cells in said cell culture comprise a polynucleotide encoding amino acids 1-285 of SEQ ID NO:2 operably associated with a regulatory sequence that controls gene expression.

167. (Previously Presented) The method of claim 166 wherein the antibody or portion thereof is a monoclonal antibody.

168. (Previously Presented) The method of claim 166 wherein the antibody or portion thereof is a polyclonal antibody.

169. (Previously Presented) The method of claim 166 wherein the antibody or portion thereof is a Fab fragment.

170. (Previously Presented) The method of claim 166 wherein the antibody or portion thereof is labeled.

171. (Previously Presented) The method of claim 170 wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

172. (Previously Presented) The method of claim 171 wherein the label is a radioisotope selected from the group consisting of:

(a) ^{125}I;

(b) ^{121}I;

(c) ^{131}I;

(d) ^{112}In; and

(e) ^{99m}Tc.

173. (Previously Presented) The method of claim 166 wherein the autoimmune disease or disorder is systemic lupus erythematosus.

174. (Previously Presented) A method of treating rheumatoid arthritis comprising administering to an individual, an effective amount of an antagonistic antibody or portion thereof that specifically binds to an isolated recombinant Neutrokine-α protein purified from a cell culture wherein the cells in said cell culture comprise a polynucleotide encoding amino acids 1-285 of SEQ ID NO:2 operably associated with a regulatory sequence that controls gene expression.

175. (Previously Presented) The method of claim 174 wherein the antibody or portion thereof is a monoclonal antibody.

176. (Previously Presented) The method of claim 174 wherein the antibody or portion thereof is a polyclonal antibody.

177. (Previously Presented) The method of claim 174 wherein the antibody or portion thereof is a Fab fragment.

178. (Previously Presented) The method of claim 174 wherein the antibody or portion thereof is labeled.

179. (Previously Presented) The method of claim 178 wherein the label is selected from the group consisting of:

(a) an enzyme label;

(b) a radioisotope;

(c) a fluorescent label; and

(d) biotin.

180. (Previously Presented) The method of claim 179 wherein the label is a radioisotope selected from the group consisting of:

(a) ^{125}I;

(b) ^{121}I;

(c) ^{131}I;

(d) ^{112}In; and

(e) ^{99m}Tc.

181-182. (Cancelled)

183. (Previously Presented) The method of claim 148 which comprises administering to an individual an effective amount of said antagonistic antibody or portion thereof.

184. (Previously Presented) The method of claim 148 which comprises administering to a cell culture containing B lymphocytes an effective amount of said antagonistic antibody or portion thereof.

185. (Previously Presented) The method of claim 158 which comprises administering to an individual an effective amount of said antagonistic antibody or portion thereof.

186. (Previously Presented) The method of claim 158 which comprises administering to a cell culture containing B lymphocytes an effective amount of said antagonistic antibody or portion thereof.

187. (New) The method of claim 85 wherein said antibody or portion thereof is administered intravenously.

188. (New) The method of claim 85 which comprises administering between 0.1 and 20 mg/kg of the patient's body weight of said antibody or portion thereof.

189. (New) The method of claim 118 wherein said antibody or portion thereof is administered intravenously.

190. (New) The method of claim 118 which comprises administering between 0.1 and 20 mg/kg of the patient's body weight of said antibody or portion thereof.

191. (New) The method of claim 166 wherein said antibody or portion thereof is administered intravenously.

192. (New) The method of claim 166 which comprises administering between 0.1 and 20 mg/kg of the patient's body weight of said antibody or portion thereof.

193. (New) The method of claim 174 wherein said antibody or portion thereof is administered intravenously.

194. (New) The method of claim 174 which comprises administering between 0.1 and 20 mg/kg of the patient's body weight of said antibody or portion thereof.